Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease

Bone Marrow Transplantation

Volumn 23, Issue 11, 1999, Pages 1131-1138

  Reece, D E ^a,c   Nevill, T J ^a   Sayegh, A ^a   Spinelli, J J ^a   Brockington, D A ^a   Barnett, M J ^a   Klingemann, H G ^a   Connors, J M ^b   Nantel, S H ^a   Shepherd, J D ^a   Sutherland, H J ^a   Voss, N J S ^a   Fairey, R N ^a   O'Reilly, S E ^b   Phillips, G L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Autotransplantation; Hodgkin's disease; Non relapse mortality; Toxicity

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; NITROSOUREA;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG FATALITY; DRUG TOXICITY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RELAPSE; RISK FACTOR;

EID: 0033047988     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701790     Document Type: Article

References (49)

1. Jagannath S, Dicke KA, Armitage JO et al. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 1986; 104: 163-168.
2. Carella AM, Congiu AM, Gaozza E et al. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian Study Group report. J Clin Oncol 1986; 6: 1411-1416.
3. Phillips GL, Wolff SN, Herzig RH et al. Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 1989; 73: 2086-2092.
4. Jones RJ, Piantadosi S, Mann RB et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1990; 8: 527-537.
5. Reece DE, Barnett MJ, Connors JM et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991; 9: 1871-1879.
6. Gianni AM, Siena S, Bregni M et al. Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease. Ann Oncol 1991; 2: 645-653.
7. Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center 8-year study of 155 patients. Blood 1993; 81: 1137-1145.
8. Rapoport AP, Rowe JM, Kouides PA et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pre-transplant disease status for predicting outcome. J Clin Oncol 1993; 11: 2351-2361.
9. Bierman PJ, Bagin RG, Jagannath S et al. High-dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long term follow-up in 128 patients. Ann Oncol 1993; 4: 767-773.
10. Yahalom J, Gulati SC, Toia M et al. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 1993; 11: 1062-1070.
11. Crump M, Smith AM, Brandwein J et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol 1993; 11: 704-711.
12. Reece DE, Connors JM, Spinelli JJ et al. Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83: 1193-1199.
13. Reece, DE, Barnett MJ, Shepherd JD et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV ± P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 1995; 86: 451-456.
14. Nademanee A, O'Donnell MR, Snyder DS et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease. Results in 85 patients with analysis of prognostic factors. Blood 1995; 85: 1381-1390.
15. Burns LJ, Daniels KA, McGlave PB et al. Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: factors predictive of prolonged survival. Bone Marrow Transplant 1995; 16: 13-18.
16. Horning SJ, Chao NJ, Negrin RS et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic factors. Blood 1997; 89: 801-813.
17. O'Brien ME, Milan S, Cunningham D et al. High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease - a pragmatic prognostic index. Br J Cancer 1996; 73: 1272-1277.
18. Wheeler C, Eickhoff C, Elias A et al. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant 1997; 3: 98-106.
19. Pecego R, Hill R, Appelbaum FR et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1986; 42: 515-517.
20. Harden E, Bolwell B, Fay J et al. Treatment of progressive Hodgkin's disease (HD) with cyclophosphamide (C), BCNU (B), and continuous infusion etoposide (V): CBVi and autologous marrow transplantation (AMT). Proc Am Soc Clin Oncol 1990; 9: 27 (Abstr.).
21. Sutcliffe SB, Wrigley PF, Peto J et al. MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J 1978; 1: 679-683.
22. Bearman SI, Appelbaum FR, Back A et al. Regimen-related toxicity and early post-transplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 1989; 7: 1288-1294.
23. Nevill TJ, Barnett MJ, Klingemann HG et al. Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 1991; 9: 1224-1232.
24. Kaplan EC, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
25. Jones RJ, Lee KSK, Beschorner WE et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
26. Phillips GL, Fay JW, Herzig GP et al. Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU), NSC # 4366650 and cryopreserved autologous marrow transplantation for refractory cancer: a phase I-II study. Cancer 1983; 52: 1792-1802.
27. Jones RB, Matthes S, Shpall EJ et al. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst 1993; 85: 640-647.
28. Meisenberg BR, Miller WE, McMillan R et al. Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies. J Clin Oncol 1997; 15:11-17.
29. Weaver CH, Appelbaum FR, Petersen FB et al. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol 1993; 11: 1329-1335.
30. Chao NJ, Duncan SR, Long GD et al. Corticosteroid therapy for diffuse alveolar hemorrhage in bone marrow transplant recipients. Ann Intern Med 1991; 114: 145-146.
31. Wheeler C, Antin JH, Churchill WH et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990; 8: 648-656.
32. O'Driscoll BR, Hasleton PS, Taylor PM et al. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. New Engl J Med 1990; 323: 378-382.
33. Ager S, Mahendra P, Richards EM et al. High-dose carmustine, etoposide and melphalan (BEM) with autologous stem cell transplantation: a dose toxicity study. Bone Marrow Transplant 1996; 17: 335-340.
34. Rubio C, Hill ME, Milan S et al. Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's disease. Br J Cancer 1997; 75: 1044-1048.
35. Reece D. Should high risk patients with Hodgkin's disease be singled out for heavier therapeutic regimens while low risk patients are spared such therapies? Leuk Lymphoma 1995; 15 (Suppl. 1): 19-21.
36. Schiffman K, Buckner CD, Maziarz R et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Biol Blood Marrow Transplant 1997; 3: 261-266.
37. Bennett CL, Armitage JL, Armitage JO et al. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 to 1991. J Clin Oncol 1995; 13: 969-973.
38. Sweetenham JW, Taghipour G, Milligan D et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse: results from the EBMT. Bone Marrow Transplant 1997; 20: 745-752.
39. Schulof RS, Bockman RS, Garofalo JA et al. Multivariate analysis of T-cell functional defects and circulating serum factors in Hodgkin's disease. Cancer 1981; 48: 964-973.
40. Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998; 92: 1471-1490.
41. Darrington DL, Vose JM, Anderson JR et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12: 2527-2534.
42. Miller JS, Arthur DC, Litz CE et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 1994; 83: 3780-3786.
43. Traweek ST, Slovak ML, Nademanee AP et al. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood 1994; 84: 957-963.
44. Andre M, Henry-Amar M, Blaise D et al. Treatment-related deaths and second cancer risk after autologous stem cell transplantation for Hodgkin's disease. Blood 1998; 92: 1933-1940.
45. Radford JE Jr, Abruzzese EA, Pettenati MJ et al. Presence in pre-transplant marrow of abnormal progenitor cell clones which give rise to post-transplant myelodysplasia. Implications for high-dose chemotherapy with autologous hematopoietic stem cell transplantation. In: Keating A, Dicke KA (eds). Proceedings Ninth International Symposium on Autologous Blood and Marrow Transplantation, Dallas, TX, July 1998.
46. Bhatia S, Ramsay NK, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633-3639.
47. Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 1997; 8 (Suppl. 1): 5115-5118.
48. De Vita VT Jr. Late sequelae of treatment of Hodgkin's disease. Curr Opin Oncol 1997; 9: 428-431.
49. van Leeuwen FE, Klokman WJ, Hagenbeek A et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994; 12: 312-325.